Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 153

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 2
Chunk 153
---
1,860  
    $25  
    $2,776  
    $153 
  
    General and administrative expenses 
     3,092  
     3,115  
     5,792  
     5,942 
  
    Total operating costs and expenses 
     4,952  
     3,140  
     8,568  
     6,095 
  
    Operating loss 
     (4,952) 
     (3,140) 
     (8,568) 
     (6,095)
  
    Other income (expenses): 

    Other income (expense), net 
     (1,023) 
     (2,126) 
     (1,992) 
     (2,613)
  
    Interest Income 
     4  
     2  
     12  
     11 
  
    Interest expense, net 
     (57) 
     (119) 
     (233) 
     (238)
  
    Total other (expense) income, net 
     (1,076) 
     (2,243) 
     (2,213) 
     (2,840)
  
    Net loss 
    $(6,028) 
    $(5,383) 
    $(10,781) 
     (8,935)

Comparison
of the Three Months Ended June 30, 2025 and 2024

Research
and Development Expenses

    Three Months ended  June 30,  
    Change 
  
    (Dollar amounts in thousands) 
    2025  
    2024  
    Amount  
    % 
  
    Research and development expenses 
    $1,860  
    $25  
    $1,835  
     7,340%

Research
and development expenses increased by $1.8 million, or 7,340%, for the three months ended June 30, 2025, as compared to $25 thousand
for the three months ended June 30, 2024. The increase was primarily due $1.6 million of expense recorded under the Sarborg Service Agreement
and Sarborg Additional Agreement and $0.1 million of expense recorded under the Thesprogen Agreement, and $0.1 million in other research and development related activity.

General